NCT06310343
ADAs to Alemtuzumab
A Study of a New Assay to Detect Anti-drug Antibodies to Alemtuzumab and Their Potential Impact in Multiple Sclerosis
Queen Mary University of London·ClinicalTrials.gov·drugRecruitment Completed
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Multiple Sclerosis
- Drug/Device/Intervention
- Alemtuzumab
- Study type
- Observational
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Queen Mary University of London
- Location
- London, United Kingdom
Timeline & enrollment
- Phase
- N/A
- Start date
- Apr 25, 2022
- End date
- Nov 30, 2025
- Enrollment
- 15 participants
Primary outcome
To quantify the longitudinal changes in alemtuzumab ADAs
Summary
The main aim is to quantify the changes in alemtuzumab antibody-anti-alemtuzumab over a 24
 months period
ICD-10 classifications
Multiple sclerosisProgressive systemic sclerosisSystemic sclerosisSystemic sclerosis, unspecifiedDiffuse sclerosis
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06310343
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06310343 through Pure Global AI's free database. This phase not specified trial is sponsored by Queen Mary University of London and is currently Recruitment Completed. The study focuses on Multiple Sclerosis. Target enrollment is 15 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.